{
    "organizations": [],
    "uuid": "7d5a3a623ab15e6358e9239217e2ad315679ed67",
    "author": "",
    "url": "https://www.reuters.com/article/brief-helix-biopharma-corp-announces-reg/brief-helix-biopharma-corp-announces-regulatory-approval-to-dose-patients-in-a-phase-ii-randomized-study-of-l-dos47-with-vinorelbine-and-cisplatin-idUSFWN1RN07Z",
    "ord_in_thread": 0,
    "title": "BRIEF-Helix Biopharma Corp. Announces Regulatory Approval To Dose Patients In A Phase II Randomized Study of L-DOS47 With Vinorelbine And Cisplatin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News April 10, 2018 / 11:47 AM / in 8 minutes BRIEF-Helix Biopharma Corp. Announces Regulatory Approval To Dose Patients In A Phase II Randomized Study of L-DOS47 With Vinorelbine And Cisplatin Reuters Staff 1 Min Read \nApril 10 (Reuters) - Helix Biopharma Corp: \n* HELIX BIOPHARMA CORP. ANNOUNCES REGULATORY APPROVAL TO DOSE PATIENTS IN A PHASE II RANDOMIZED STUDY OF L-DOS47 WITH VINORELBINE AND CISPLATIN \n* ALL NECESSARY REGULATORY AND ETHICS APPROVALS HAVE BEEN RECEIVED TO DOSE FIRST PATIENT IN ITS LDOS003 TRIAL IN UKRAINE Source text for Eikon: Further company coverage:",
    "published": "2018-04-10T14:45:00.000+03:00",
    "crawled": "2018-04-10T15:06:54.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "april",
        "minute",
        "biopharma",
        "announces",
        "regulatory",
        "approval",
        "dose",
        "patient",
        "phase",
        "ii",
        "randomized",
        "study",
        "vinorelbine",
        "cisplatin",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "helix",
        "biopharma",
        "corp",
        "helix",
        "biopharma",
        "announces",
        "regulatory",
        "approval",
        "dose",
        "patient",
        "phase",
        "ii",
        "randomized",
        "study",
        "vinorelbine",
        "cisplatin",
        "necessary",
        "regulatory",
        "ethic",
        "approval",
        "received",
        "dose",
        "first",
        "patient",
        "ldos003",
        "trial",
        "ukraine",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}